- Home
- JACK vs ETNB Comparison
JACK vs ETNB Comparison
Compare JACK & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JACK
- ETNB
- Stock Information
- Founded
- JACK 1951
- ETNB 2018
- Country
- JACK United States
- ETNB United States
- Employees
- JACK N/A
- ETNB N/A
- Industry
- JACK Restaurants
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- JACK Consumer Discretionary
- ETNB Health Care
- Exchange
- JACK Nasdaq
- ETNB Nasdaq
- Market Cap
- JACK 997.4M
- ETNB 867.4M
- IPO Year
- JACK 1987
- ETNB 2019
- Fundamental
- Price
- JACK $45.15
- ETNB $7.19
- Analyst Decision
- JACK Buy
- ETNB Strong Buy
- Analyst Count
- JACK 18
- ETNB 8
- Target Price
- JACK $68.71
- ETNB $30.14
- AVG Volume (30 Days)
- JACK 540.1K
- ETNB 615.2K
- Earning Date
- JACK 11-19-2024
- ETNB 11-06-2024
- Dividend Yield
- JACK 3.91%
- ETNB N/A
- EPS Growth
- JACK N/A
- ETNB N/A
- EPS
- JACK N/A
- ETNB N/A
- Revenue
- JACK $1,594,540,000.00
- ETNB N/A
- Revenue This Year
- JACK N/A
- ETNB N/A
- Revenue Next Year
- JACK N/A
- ETNB $133.30
- P/E Ratio
- JACK N/A
- ETNB N/A
- Revenue Growth
- JACK N/A
- ETNB N/A
- 52 Week Low
- JACK $40.84
- ETNB $6.58
- 52 Week High
- JACK $86.20
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- JACK 45.71
- ETNB 33.24
- Support Level
- JACK $43.33
- ETNB $7.00
- Resistance Level
- JACK $47.84
- ETNB $7.57
- Average True Range (ATR)
- JACK 1.49
- ETNB 0.37
- MACD
- JACK 0.47
- ETNB -0.06
- Stochastic Oscillator
- JACK 43.43
- ETNB 11.66
About JACK Jack In The Box Inc.
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants in California, the USA under the brands Jack in the Box. The company menu offers burgers, tacos, regular and curly fries, specialty sandwiches, salads and ice cream shakes. These foods are available with the option of customization as per customer requirements. The company also offer catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two operating segments, out of which Jack in the box generates maximum revenue.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).